Loading…

Cardiac biomarkers as indicators of right ventricular dysfunction and recovery in chronic thromboembolic pulmonary hypertension patients after balloon pulmonary angioplasty therapy – a cardiac magnetic resonance imaging cohort study

Background In chronic thromboembolic pulmonary hypertension, right heart failure determines outcome. Balloon pulmonary angioplasty therapy allows right heart recovery, which can be monitored by cardiac magnetic resonance imaging. This study evaluates whether cardiac biomarkers (NT-proBNP, MR-proANP,...

Full description

Saved in:
Bibliographic Details
Published in:Pulmonary circulation 2021-10, Vol.11 (4), p.1-10
Main Authors: Kriechbaum, Steffen D., Vietheer, Julia M., Wiedenroth, Christoph B., Rudolph, Felix, Barde, Marta, Wolter, Jan-Sebastian, Haas, Moritz, Fischer-Rasokat, Ulrich, Weferling, Maren, Rolf, Andreas, Hamm, Christian W., Mayer, Eckhard, Guth, Stefan, Keller, Till, Roller, Fritz C., Liebetrau, Christoph
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background In chronic thromboembolic pulmonary hypertension, right heart failure determines outcome. Balloon pulmonary angioplasty therapy allows right heart recovery, which can be monitored by cardiac magnetic resonance imaging. This study evaluates whether cardiac biomarkers (NT-proBNP, MR-proANP, sST2, and PAPP-A) are associated with cardiac magnetic resonance imaging findings prior to and after balloon pulmonary angioplasty therapy. Methods This observational cohort study enrolled 22 chronic thromboembolic pulmonary hypertension patients who underwent balloon pulmonary angioplasty therapy and completed a six-month follow-up including cardiac magnetic resonance imaging. Biomarker levels were compared with findings for right heart morphology and function derived from cardiac magnetic resonance imaging. Results Pulmonary hemodynamics improved after balloon pulmonary angioplasty therapy [pulmonary vascular resistance: 7.7 (6.0–9.0) vs. 4.7 (3.5–5.5) wood units, p 
ISSN:2045-8940
2045-8932
2045-8940
DOI:10.1177/20458940211056500